Ocugen, Inc. unveils 12-month Phase 2 data for OCU410 gene therapy in GA

Ocugen, Inc. unveils 12-month Phase 2 data for OCU410 gene therapy in GA
Ocugen, Inc. delivers Phase 2 data

Ocugen, Inc. announced encouraging 12-month results from its Phase 2 trial of OCU410, a one-time gene therapy targeting geographic atrophy (GA).

Initial data indicate a measurable impact on both lesion growth and visual function, reinforcing OCU410's potential to shift the treatment paradigm for GA and serve unmet patient needs. The company continues to advance development efforts and will release further data as the study progresses.

Ocugen has previously accelerated development of modifier gene therapies to treat major blindness diseases, addressing rising concerns around eye health, according to a recent article. The company has also pledged support for Rare Disease Day and continues to advance gene therapies for rare inherited retinal conditions, as highlighted in a recent report. These efforts reflect Ocugen's continued focus on innovation in the treatment of retinal diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.